Mural Oncology (MURA) Income Statement (2022 - 2025)
Income Statement report data from Mar 31, 2022 to Sep 30, 2025 for Mural Oncology (MURA).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||||
Research And Development | - | 23M (-15.13%) | 27M (-4.33%) | 29M (+3.91%) | 28M (+0.18%) | 28M (+2.49%) | 27M (-36.39%) | 42M (+4.68%) | 40M (-5.13%) | 43M (+5.25%) | 40M (-66.99%) | 122M (+173.44%) | 45M | - | - |
Selling General And Administrative | 8.25M (+2.10%) | 8.08M (+16.09%) | 6.96M (-3.20%) | 7.19M (+10.45%) | 6.51M (-3.27%) | 6.73M (-6.14%) | 7.17M (-55.93%) | 16M (+172.99%) | 5.96M (+26.00%) | 4.73M (+26.13%) | 3.75M (-71.59%) | 13M (+191.39%) | 4.53M | - | - |
Operating Expenses | 3.97M (-91.87%) | 49M (+42.06%) | 34M (-4.10%) | 36M (+5.13%) | 34M (-0.53%) | 34M (+0.73%) | 34M (-41.84%) | 59M (+26.34%) | 46M (-2.01%) | 47M (+7.02%) | 44M (-67.44%) | 136M (+175.09%) | 49M | - | - |
Depreciation And Amortization | 800K (-27.27%) | 1.10M (+29.41%) | 850K (-2.30%) | 870K (-3.33%) | 900K (0.00%) | 900K (+5.88%) | 850K (+57.41%) | 540K (-32.50%) | 800K (+14.29%) | 700K (+32.08%) | 530K (-65.58%) | 1.54M | - | - | - |
Operating Income | |||||||||||||||
Operating Income | -3.97M (-91.87%) | -48.84M (+42.06%) | -34.38M (-4.10%) | -35.85M (+5.13%) | -34.10M (-0.53%) | -34.28M (+0.73%) | -34.03M (-41.84%) | -58.51M (+26.34%) | -46.31M (-2.01%) | -47.26M (+7.02%) | -44.16M (-67.44%) | -135.62M (+175.09%) | -49.30M | - | - |
Ebit | -3.97M (-91.87%) | -48.84M (+42.06%) | -34.38M (-4.10%) | -35.85M (+5.13%) | -34.10M (-0.53%) | -34.28M (+0.73%) | -34.03M (-41.84%) | -58.51M (+26.34%) | -46.31M (-2.01%) | -47.26M (+7.02%) | -44.16M (-1.95%) | -45.04M (-8.64%) | -49.30M (+13.80%) | -43.32M (-8.34%) | -47.26M |
EBITDA | -3.17M (-93.36%) | -47.74M (+42.38%) | -33.53M (-4.17%) | -34.99M (+5.39%) | -33.20M (-0.54%) | -33.38M (+0.57%) | -33.19M (-42.75%) | -57.97M (+27.38%) | -45.51M (-2.26%) | -46.56M (+6.72%) | -43.63M (+0.30%) | -43.50M (-11.76%) | -49.30M (+13.80%) | -43.32M (-8.34%) | -47.26M |
Other Income / Expenses | |||||||||||||||
Other Non Operating Income | 260K (-69.77%) | 860K (-31.20%) | 1.25M (-87.18%) | 9.75M (+316.67%) | 2.34M (-13.65%) | 2.71M (-13.14%) | 3.12M (+228.42%) | 950K | - | - | - | - | - | - | - |
Net Income | |||||||||||||||
Income Before Tax | - | - | - | -128.51M | - | - | - | -195.29M | - | - | - | -184.92M | - | - | - |
Income Tax Expense | - | - | - | - | - | - | - | 1.98M (-60.16%) | 4.97M (+70.79%) | 2.91M (+25.97%) | 2.31M (-34.75%) | 3.54M (+164.18%) | 1.34M | - | - |
Net Income From Continuing Operations | -3.71M (-92.27%) | -47.98M (+44.78%) | -33.14M (-3.30%) | -34.27M (+7.90%) | -31.76M (+0.63%) | -31.56M (+2.07%) | -30.92M (-48.07%) | -59.54M (+16.11%) | -51.28M (+2.99%) | -49.79M (+6.30%) | -46.84M (-3.58%) | -48.58M (-4.07%) | -50.64M (+16.90%) | -43.32M (-8.34%) | -47.26M |
Net Income | -3.71M (-92.27%) | -47.98M (+44.78%) | -33.14M (-3.30%) | -34.27M (+7.90%) | -31.76M (+0.63%) | -31.56M (+2.07%) | -30.92M (-48.07%) | -59.54M (+16.11%) | -51.28M (+2.99%) | -49.79M (+6.30%) | -46.84M (-3.58%) | -48.58M (-4.07%) | -50.64M (+16.90%) | -43.32M (-8.34%) | -47.26M |
Comprehensive Income Net Of Tax | -3.71M (-92.27%) | -47.98M (+44.69%) | -33.16M (-74.19%) | -128.49M (+305.84%) | -31.66M (+0.38%) | -31.54M (+1.77%) | -30.99M (-85.06%) | -207.45M (+304.54%) | -51.28M (+2.23%) | -50.16M (+7.94%) | -46.47M | - | - | - | - |